ReNeuron Group plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RENE.L research report →
Companywww.reneuron.com
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in the partnering stage in china and outside china for treating stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells.
- CEO
- Iain Gladstone Ross BSc C.DIR, CH.D
- IPO
- 2005
- Employees
- 26
- HQ
- Pencoed, GB
Price Chart
Valuation
- Market Cap
- $1.93M
- P/E
- -0.01
- P/S
- 0.09
- P/B
- 0.01
- EV/EBITDA
- 0.89
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -742.08%
- Op Margin
- -1342.45%
- Net Margin
- -1020.38%
- ROE
- -72.37%
- ROIC
- -105.51%
Growth & Income
- Revenue
- $530.00K · 31.51%
- Net Income
- $-5,408,000 · 44.18%
- EPS
- $-0.09 · 44.29%
- Op Income
- $-7,115,000
- FCF YoY
- 0.12%
Performance & Tape
- 52W High
- $8.00
- 52W Low
- $3.38
- 50D MA
- $0.03
- 200D MA
- $1.03
- Beta
- 0.70
- Avg Volume
- 0
Get TickerSpark's AI analysis on RENE.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our RENE.L Coverage
We haven't published any research on RENE.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RENE.L Report →